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ObjectiveaaTo determine if the maintenance effectiveness and tolerability of aripiprazole demonstrated in a 12-week study were main-
tained in an extension phase (up to 26 weeks).
MethodsaaThis study was the extension of our switching study from other antipsychotics to aripiprazole in symptomatically stable patients 
with schizophrenia or schizoaffective disorder. All the patients were randomly assigned to the aripiprazole group or the non-aripiprazole 
group. The effectiveness analysis consisted of the comparison of the upper bound of the 95% confidence interval (CI) of the mean Clinical 
Global Impression-Improvement (CGI-I) score to 4 (no change) at the end of the study. 
ResultsaaAt the baseline, the aripiprazole group (n=135) and the non-aripiprazole group (n=31) were comparable with respect to their 
mean ages, gender distribution, baseline Positive and Negative Syndrome Scale scores, and Clinical Global Impression-Severity (CGI-S) 
scores. The study showed that the mean CGI-I score was 2.92 (95% CI: 2.72-3.12) in the aripiprazole group and 2.81 (95% CI: 2.35-3.26) in 
the non-aripiprazole group at 26 weeks. In the aripiprazole group, the remission rates at 12 and 26 weeks were 74.8% and 72.6%, respectively, 
and 80.2% of the patients with remission at 12 weeks maintained their remission state until the end of the study. About one-fourth of the 
patients in the aripiprazole group reported one or more spontaneous treatment-emergent adverse events, such as insomnia, headache, 
and nausea.
ConclusionaaThis study suggested that most clinically stable outpatients with schizophrenia maintain their remission states after being 
switched to aripiprazole, without serious symptom aggravation and adverse events over a course of 26 weeks.
Psychiatry Investig 2010;7:189-195
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INTRODUCTION
Aripiprazole, an atypical antipsychotic, is known to be effec-
tive for the maintenance treatment as well as acute treatments 
of schizophrenia. Aripiprazole has been demonstrated to be safe 
and efficacious in previous studies, including short-term stud-
ies,
1,2 a 26-week placebo-controlled clinical trial,
3 and a long-
term, 52-week, haloperidol-controlled study.
4 According to the 
results of a 52-week, open-label extension to a 26-week, dou-
ble-blind, randomized, placebo-controlled study in patients 
with schizophrenia, aripiprazole showed a similar efficacy to 
olanzapine for the long-term treatment of acutely psychotic and 
chronic, stable schizophrenia patients.
5
Aripiprazole has also been demonstrated to have a relatively 
low rate of extrapyramidal symptoms (EPSs) and a low pro-
pensity for weight gain and prolactin-related adverse events.
1,4-8 
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These study findings suggest that aripiprazole may be an ap-
propriate drug for the maintenance treatment of schizophrenia.
One of methods to investigate the maintenance efficacy of 
antipsychotics is to examine the changes in the symptoms or ad-
verse events after switching from one antipsychotic to another 
in patients with stable symptoms. To investigate the mainte-
nance effectiveness of aripiprazole, we conducted a prospective, 
non-comparative, open-label study switching from a previ-
ous antipsychotic agent to aripiprazole in schizophrenic Ko-
rean patients who were symptomatically stable. The early 12-
week results of the study demonstrated that majority of the pa-
tients were successfully switched from their previous antipsy-
chotics to aripiprazole without serious symptom exacerba-
tion or adverse events over a course of 12 weeks.
9
The aims of this paper were to evaluate whether the previ-
ously published results of a 12-week study on the maintenance 
effectiveness and tolerability of aripiprazole would be main-
tained up to 26 weeks in the patients who consented to par-
ticipate in a 12-week extension study.
METHODS
Study design
The design of this study was similar to those of the Broad Ef-
fectiveness Trial with Aripiprazole (BETA) and EU-BETA stud-
ies,
10,11 except that the study duration was 26 weeks rather than 
8 weeks.
This randomized, open-label, multicenter, 26-week study was 
designed to evaluate the maintenance efficacy and tolerability 
of aripiprazole when symptomatically stable patients with 
schizophrenia or schizoaffective disorder were switched from 
their previous prescribed oral antipsychotics to aripiprazole. 
The trial was conducted at 26 centers throughout Korea.
Subjects
The subjects who met all the following criteria were eligible 
for this study: 1) age: ≥18 years and ≤65 years; 2) diagnosis of 
schizophrenia or schizoaffective disorder (Diagnostic and 
Statistical Manual of Mental Disorders, Fourth Edition, DSM-
IV criteria) requiring long-term antipsychotic treatment; 3) 
symptomatically stable on a constant dose of antipsychotics 
for at least one month; and 4) non-admission to a hospital 
for at least three months prior to the study. The subjects were 
excluded from this study if they: 1) were undergoing their 
first treatment with an antipsychotic agent; 2) had taken clo-
zapine during the last three months; 3) had unstable medical 
conditions; 4) had a history of tardive dyskinesia or neurolep-
tic malignant syndrome; or 5) were pregnant or breastfeeding.
All the patients who were assigned to the aripiprazole group 
were prescribed a starting dose of 10 mg, with gradual dose 
adjustment allowed within a range of 10-30 mg/day at the dis-
cretion of the investigator’s judgment during the 26-week trial. 
The patients who were randomized to the non-aripiprazole 
group were treated with medications that they had not rece-
ived in their prior treatment, in accordance with the generally 
accepted clinical practice. The patients were gradually discon-
tinued from their previous antipsychotic medication during 
the first two weeks after randomization.
Of the 292 randomized patients, 186 (63.7%) completed the 
previous 12-week trial (Fig. 1). At 12 weeks (baseline of the ex-
293 patients
screened
292 patients
4 : 1 randomization
Aripiprazole (n=245) Non-aripiprazole (n=47)
Drop outs before prescription or no post-baseline measurement
Inclusion criteria
-  DSM-IV schizophrenia and  
schizoaffective disorder
-Age: 18-65 years
-  No hospitalization during last  
3 months
-  Clinically stable and same dosage  
during last 1 month
Multi-center 
(26 sites)
Switching study (baseline-12 weeks)
Extension periods (12 weeks-26 weeks)
Aripiprazole (n=226) Non-aripiprazole (n=44)
Aripiprazole (n=135) Non-aripiprazole (n=31)
Aripiprazole (n=119) Non-aripiprazole (n=28)
Figure 1. Design overview and enrollment of this study. This extension study was conducted with 166 patients who had completed the 
switching study and given written consent to the extension study.JS Lee et al. 
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tension study), a written informed consent was again obtained 
from the patients who agreed to participate in the extension st-
udy. Of the 186 patients completing the 12-week treatment ph-
ase, 166 agreed to enroll to long-term extension study. This 14-
week extension study was approved by respective institutional 
review boards.
Efficacy and safety measurements
The symptoms, functions, and adverse events of the subjects 
were assessed monthly based on the Clinical Global Impres-
sion-Improvement/Severity scale (CGI-I/CGI-S), Positive and 
Negative Syndrome Scale (PANSS), Global Assessment of 
Functioning (GAF), Udvalg for Kliniske Undersogelser (UKU) 
side effect rating scale, and treatment-emergent adverse events 
(TEAEs).
The primary outcome measure in this study was the mean 
CGI-I score at 26 weeks in the aripiprazole group. The effec-
tiveness analysis consisted of a comparison of the upper bound 
of the 95% confidence interval (CI) of the mean CGI-I score 
to 4 (no change) at the end of the study. The secondary out-
come measures included the mean changes from the baseline 
to the end of the study in the PANSS total score and the CGI-S 
score. The symptom remission and worsening rates were also 
estimated at 26 weeks, using the definition of remission and 
worsening indicated below. Remission was defined as 1) PA-
NSS total score ≤60; 2) CGI severity score ≤3 (mild); and 3) 
no rating ≥4 (moderate) on any of the four PANSS psychotic 
items (delusion, conceptual disorganization, hallucinatory be-
havior, suspiciousness/persecution). Symptom worsening was 
defined as 1) ≥20% increase from the baseline in the PANSS 
total score; 2) any change ≥2 points on any of the four PANSS 
psychotic items (excluding the changes in which the ratings 
remained at nonpsychotic levels; mild, i.e. ≤3); 3) CGI-I score 
≥6 (much worse); or 4) discontinuation due to lack of efficacy.
Data analysis
The baseline clinical and epidemiological characteristics of 
the aripiprazole and non-aripiprazole groups in this extension 
study were compared using the Student’s t-test for the contin-
uous variables and the χ2 test for the categorical variables. The 
last-observation-carried-forward (LOCF) convention was used 
to analyze the mean CGI-I score and the mean changes in the 
CGI-S and PANSS scores during this extension study.
An upper bound of 95% CI of the CGI-I score <4 at 26 
weeks was considered an indicator of effectiveness in the ar-
ipiprazole group. The between-group differences in the mean 
changes in the CGI-S and PANSS scores were evaluated via re-
peated-measures analysis of covariance (ANCOVA), with the 
baseline score of each scale as the covariate. The within-group 
changes from 12 weeks (baseline of the extension study) to 26 
weeks were analyzed via the paired t-test or Wilcoxon’s signed 
rank test for the continuous variables and McNemar’s test for 
the categorical variables.
The rate of remission was calculated based on the propor-
tion of patients who met the criteria for remission at 26 weeks 
relative to 12 weeks. The rate of symptom worsening was cal-
culated, according to the lifetime method, as 100×number of 
patients who met the worsening criteria at each visit/[number 
of observed subjects at each visit-1/2 (number of dropouts be-
tween the last visit and the current visit-number of dropouts 
due to lack of efficacy)]. Tolerability and safety analysis was 
performed for the patients who were prescribed at least one 
dose of aripiprazole or another antipsychotic. The occurrence 
of an adverse event was defined as score ≥2 (moderate) in 
each item of UKU. Kaplan-Meier survival analysis was per-
formed to estimate the cumulative rate of remission and to 
investigate the time-to-failure-to-maintain-remission in the 
patients who met the remission criteria at 12 weeks, the time-
to-discontinuation for any cause in all the intention-to-treat 
(ITT) patients, and the time-to-symptom-worsening in all the 
ITT patients.
RESULTS
At the baseline of this extension study, 135 patients were pre-
scribed aripiprazole, and 31 patients were prescribed non-ari-
piprazole antipsychotics (Fig. 1). The two groups were com-
parable with respect to their mean ages, gender distribution, 
baseline PANSS scores, and CGI-S scores (Table 1).
Of 166 patients, 147 (aripiprazole, n=119; non-aripiprazole, 
n=28) completed this extension study. The most common rea-
sons for drop outs in the aripiprazole group were lost to follow-
up (n=6, 37.5%) and lack of efficacy (n=5, 31.3%).
Efficacy
At 26 weeks, the LOCF analysis showed that the mean CGI-
I score was 2.92±1.16 (95% CI: 2.72, 3.12) in the aripiprazole 
group and 2.81±1.25 (95% CI: 2.35, 3.26) in the non-aripip-
razole group. There was no significant difference between the 
aripiprazole and non-aripiprazole groups in terms of the ch-
anges in their CGI-S scores over time (group×time interaction, 
repeated-measures ANCOVA with the score at 12 weeks as the 
covariate, p=0.10). The CGI-S scores were significantly decre-
ased over time, however, in the patients in the non-aripipra-
zole group, and were not in the aripiprazole group (Fig. 2).
Repeated-measures ANOVA was performed to compare the 
changes in the PANSS scores over time between the two groups. 
No significant difference was found in the mean PANSS total 
score, positive, negative, and general subscale scores in the ari-
piprazole group, but the mean PANSS total score and positive, 192  Psychiatry Investig 2010;7:189-195
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negative, and general subscale scores significantly decreased 
over time in the non-aripiprazole group (p<0.01, all). There 
was no significant group×time interaction, however, in the 
PANSS total and subscale scores (p<0.05, all).
In the aripiprazole group, the remission rate was 74.8% 
(101/135) at 12 weeks and 72.6% (98/135, dropouts=16) at the 
end of the study. Of the patients with aripiprazole who were 
in remission at 12 weeks, 80.2% (n=81, dropouts=12) main-
tained their remission state until the end of the study. When 
the patients (n=34) with an insufficient response at 12 weeks 
took aripiprazole continuously without changing their anti-
psychotics until the endpoint (26 weeks), 32.4% of these pa-
tients (11/34, dropouts=4) showed further significant symp-
tom improvements and achieved a remission at the endpoint 
(Fig. 3). The symptom worsening rate at the end of the study 
was relatively low (6.4%, life table method).
According to the observed-cases analysis of the aripipra-
zole group, the overall psychosocial function scores of the pa-
tients in the group on the GAF was 69.0±11.5 at 26 weeks, and 
these significantly improved compared to their GAF scores at 
the baseline of the extension study (67.1±11.5, p<0.05).
Safety and tolerability
Safety analysis was performed on all the patients who were 
prescribed at least one post-baseline dose of aripiprazole or 
non-aripiprazole antipsychotics (aripiprazole, n=131; non-ari-
piprazole, n=31). Spontaneous TEAEs were reported by 34 
(25.2%) patients on aripiprazole, at least one TEAE from 12 
weeks to 26 weeks, and the most commonly reported adverse 
events included insomnia (n=6, 4.4%), headache (n=4, 2.9%), 
and nausea (n=4, 2.9%), whereas the most common TEAE 
Table 1. Demographic and clinical characteristics
Aripiprazole Non-aripiprazole Total p-value
Age (yrs) 35.7±9.6 37.2±11.4 36.0±9.9 0.46*
Gender 0.79**
Male 047 (34.8%) 10 (32.3%) 057 (34.3%)
Female 088 (65.2%) 21 (67.7%) 109 (65.7%)
Duration of illness (yrs) 06.3±6.3 08.0±6.2 06.6±6.3 0.17*
Diagnosis 0.49**
Schizophrenia 116 (85.9%) 29 (93.5%) 145 (87.3%)
Paranoid type 072 (53.3%) 17 (54.8%) 089 (53.6%)
Residual type 011 (8.1%) 05 (16.1%) 016 (9.6%)
Disorganized type 002 (1.5%) 01 (3.2%) 003 (1.8%)
Catatonic type 000 (0%) 00 (0%) 000 (0%)
Undifferentiated type 031 (23.0%) 06 (19.4%) 037 (22.3%)
Schizoaffective disorder 019 (14.1%) 02 (6.5%) 021 (12.7%)
Baseline (12 weeks) PANSS score
Total score 49.5±14.7 51.7±17.0 49.9±15.1 0.62*
Positive subscale 11.2±3.7 10.9±4.3 11.2±3.8 0.41*
Negative subscale 12.2±4.9 14.2±6.5 12.6±5.3 0.15*
General subscale 26.0±7.5 26.6±7.7 26.1±7.5 0.71*
Baseline (12 weeks) CGI-S 02.5±0.8 02.7±1.0 02.6±0.9 0.23*
*analyzed by student t-test, **analyzed by Chi-square test. PANSS: Positive and Negative Syndrome Scale, CGI-S: Clinical Global Impression-
Severity
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Figure 2. Changes from baseline to endpoint (LOCF). Repeated me-
asures ANOVA was performed for within group comparison (non-ari-
piprazole group, n=31, p=0.0014; aripiprazole group, n=135, p=0.8689). 
Repeated measures ANCOVA was performed for between non-ari-
piprazole group (n=31) and aripiprazole group (n=135) compari-
son with score of 12 weeks as covariate (group effect, p=0.0434; gr-
oup×time interaction effect, p=0.1034). 
Within group p<0.01
Within group p=0.877JS Lee et al. 
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in the non-aripiprazole group was dystonia (n=6, 2.5%). In the 
aripiprazole group, there were two serious adverse events (SAEs): 
suicide attempt and aggravation of psychotic disorder with 
no causal relationship between two SAEs and aripiprazole. 
There was no SAE in the non-aripiprazole group.
When the scores of the patients in the aripiprazole group on 
each item of UKU at 12 and 26 weeks were compared, the 
scores on hypokinesia, akathisia, and amenorrhea were found 
to have significantly decreased over time (Table 2). When ad-
verse events were defined as a score ≥2 on each item of UKU, 
a decrease in the prolactin-related adverse events and akathisia 
at the endpoints (p<0.05) was found in the aripiprazole gr-
oup (Table 2).
   
DISCUSSION
This study suggests that most clinically stable outpatients 
with schizophrenia maintain their remission states after being 
switched to aripiprazole, without serious symptom aggravation 
and adverse events over the course of 26 weeks of treatment. 
It was shown in this study that 80.2% (81/101) of the subjects 
maintained their remission state from 12 to 26 weeks, without 
symptom aggravation. The symptom worsening rate at the end 
of the study was 6.4%. Moreover, 32.4% of the patients with an 
Table 2. Comparisons UKU adverse event (neurologic adverse events) within group and between-groups
UKU
Aripiprazole Non-aripiprazole Between group 
p–value** N Mean±SD p-value* N Mean±SD p-value*
Dystonia 12 weeks 135 0.07±0.40 0.31 31 0.16±0.45 0.50 0.05
26 weeks 119 0.04±0.30 28 0.11±0.31
Rigidity 12 weeks 135 0.03±0.17 0.25 31 0.03±0.18 0.99 0.64
26 weeks 119 0.01±0.09 28 0.00±0.00
Hypokinesia/Akinesia 12 weeks 135 0.13±0.40 <0.01 31 0.16±0.37 0.13 0.90
26 weeks 119 0.04±0.20 28 0.04±0.19
Hyperkinesia 12 weeks 135 0.01±0.09 0.99 31 0.00±0.00 0.99 0.26
26 weeks 119 0.01±0.09 28 0.04±0.19
Tremor 12 weeks 135 0.13±0.38 0.18 31 0.10±0.30 0.99 0.88
26 weeks 119 0.09±0.32 28 0.11±0.42
Akathisia 12 weeks 135 0.12±0.41 0.02 31 0.06±0.25 0.99 0.96
26 weeks 119 0.04±0.24 28 0.04±0.19
Amenorrhea 12 weeks 084 10.7% 0.01† 16 31.2% 0.32 0.15‡
26 weeks 070 02.8% 16 12.5%
*comparisons between 12 weeks and 26 weeks using Wilcoxon signed rank test, **comparisons at end point between groups using Wilcoxon 
rank sum test , †comparisons between 12 weeks and 26 weeks using McNemar’s test, ‡comparisons at end point between groups using Fisher’s 
exact test. UKU: Udvalg for Kliniske Undersogelser side effect rating scale
Non-aripiprazole
(n=9)
66.7 55.9
32.4
Figure 3. A: Results at endpoint among remitted patients at 12 weeks. About 80-96% of patients remitted at 12 weeks maintained remission 
state until endpoint (26 weeks). B: Results at endpoint among the patients who had not remitted at 12 weeks. About 11-32% of patients who 
had not remitted at 12 weeks were converted to remission state at endpoint.
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insufficient response at 12 weeks experienced further improve-
ment and achieved remission by 26 weeks when they took ari-
piprazole continuously without changing their antipsychotic 
medication until the endpoint.
When we compared the results of our study with those of 
other naturalistic studies such as BETA, EU-BETA and the cli-
nical antipsychotic trials of intervention effectiveness (CATIE) 
although there were some differences in the definition of re-
sponse and duration of the studies, the CGI-I score of our study 
at 26 weeks (2.92, 95% CI: 2.72-3.12) was similar to those of 
BETA (2.77, 95% CI 2.68-2.86) and EU-BETA (3.16, 95% CI 
3.04-3.28) at 8 weeks
10,11 and the discontinuation rate of treat-
ment for any cause of our study at 26 weeks was slightly high-
er than that of CATIE study (49.7% vs. 40%).
12 
As mentioned above, among the patients who achieved a 
remission state at 12 weeks, approximately 20% did not main-
tain the remission. These findings are consistent with the pre-
vious findings that approximately 20% of the patients receiv-
ing aripiprazole or SGAs relapsed within six months of their 
treatment.
13,14 
We were interested in assessing the rate of symptom worsen-
ing, defined based on the PANSS total score and the psychotic 
item scores, CGI-I, and drop out due to lack of efficacy. These 
criteria (with the exception of CGI-I) were used in our previ-
ously published study on a risperidone long-acting injection 
formulation.
15 The symptom worsening rate after switching to 
aripiprazole was relatively low in our previous published study 
(12.4% at 12 weeks),
9 and this rate remained low until 26 weeks 
(6.4%) in spite of the use of more stringent criteria for symp-
tom worsening, including “drop out due to an insufficient re-
sponse.” Considering the low rate (6.4%) of symptom worsen-
ing and the relatively high (72.6%) remission rate at the end-
point (26 weeks), our results suggest that switching to aripipra-
zole from other antipsychotics is effective and tolerable in clin-
ically stable patients with schizophrenia.
Interestingly, of the patients who did not meet the remission 
criteria at the baseline of the extension study, 32.4% developed 
remission by the 26th-week follow-up while 7.9% of the pati-
ents in remission at the baseline no longer met the remission 
state.
According to the results of our study on adverse events, the 
patients who switched to aripiprazole experienced less adverse 
events at the endpoint, such as hypokinesia, akathisia, and am-
enorrhea, compared with 12 weeks. These results are consis-
tent with findings from other studies: that aripiprazole is as-
sociated with fewer EPSs or prolactin elevation.
1,4 Apart from 
EPS- and prolactin-related adverse events, aripiprazole was fo-
und to be associated with fewer metabolic side effects such as 
weight gain or increased lipid levels.
5-7 Likewise, our study sh-
owed that there was no significant change in the blood glucose 
or lipid levels in both groups for the duration of the extension 
study.
This study has a number of limitations common to a natura-
listic open, observational study: 1) The absence of a placebo 
control group made it difficult to confirm whether the rate of 
symptom worsening in the patients who were prescribed ar-
ipiprazole was lower than that in the patients with no medi-
cation. The rate of symptom worsening of this extension study 
was 7.9% at 14 weeks (about 2.6% per month). According to 
the previous reports that the monthly relapse rates were esti-
mated to be 3.5% per month for the patients on maintenance 
neuroleptics and 11.0% per month for the patients who had 
discontinued their medication,
14 the lower symptom worsen-
ing rate in this study may be due to the maintenance efficacy of 
aripiprazole rather than to the natural course of the disease. 2) 
As this study is an acute-phase extension study, 20 of the 186 
subjects who completed the acute-phase study did not agree to 
participate in the extension study. This might have affected the 
study results.
In conclusion, this study showed that the effectiveness of ari-
piprazole after a switch from other antipsychotics was main-
tained until 26 weeks. Our results also confirmed that the cli-
nically stable patients with schizophrenia were successfully 
switched from their existing antipsychotics to aripiprazole un-
til 26 weeks, without symptom worsening or serious adverse 
events.
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